WAF1 genotype and endometrial cancer susceptibility

被引:29
作者
Hachiya, T [1 ]
Kuriaki, Y [1 ]
Ueoka, Y [1 ]
Nishida, J [1 ]
Kato, K [1 ]
Wake, N [1 ]
机构
[1] Kyushu Univ, Med Inst Bioregulat, Dept Reprod Physiol & Endocrinol, Beppu, Oita 874, Japan
关键词
D O I
10.1006/gyno.1998.5247
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The WAF1 protein, which is a downstream mediator of p53, functions as a universal inhibitor of cyclin-dependent kinases. The functional link between p53 and WAF1 suggests the possibility that alteration in WAF1 function constitutes an alternative mechanism to p53 inactivation. However, there are few reports describing somatic mutations of the WAF1 gene in various human malignancies. A polymorphism in the WAF1 gene, a C-to-A transversion at codon 31 resulting in the change of a serine (Ser) to an arginine (Arg), is well known. We found this substitution in 42 of 54 endometrial carcinoma patients. Allele frequency was 0.44/0.56 for the codon 31 polymorphism (Ser/Arg), the difference of allele frequency between patients and normal controls being significant (0.59/0.41 in normal controls). In addition, individuals carrying the codon 31 Arg allele had a tendency to develop histologically high-grade (odds ratio, 6.11) and clinically advanced tumors. We investigated the association of the Arg allele with the known risk factors of endometrial carcinomas. Statistical analyses of 42 cases and 32 controls carrying the codon 31 Arg allele identified hypertension (odds ratio, 4.33) and family history of cancer (odds ratio, 2.81) as positive risk factors. This implies that these two parameters may be associated with a tendency to develop endometrial carcinomas in individuals carrying the codon 31 Arg allele of the WAF1 gene. (C) 1999 Academic Press.
引用
收藏
页码:187 / 192
页数:6
相关论文
共 33 条
[1]   The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups [J].
Birgander, R ;
Sjalander, A ;
Saha, N ;
Spitsyn, V ;
Beckman, L ;
Beckman, G .
HUMAN HEREDITY, 1996, 46 (03) :148-154
[2]  
Burke TW, 1995, J CELL BIOCHEM, P131
[3]  
CHEDID M, 1994, ONCOGENE, V9, P3021
[4]  
CHEN YQ, 1992, J BIOL CHEM, V267, P17314
[5]  
Corocleanu M., 1993, Clinical and Experimental Obstetrics and Gynecology, V20, P254
[6]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[7]  
Facher EA, 1997, CANCER, V79, P2424, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2424::AID-CNCR19>3.0.CO
[8]  
2-T
[9]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[10]  
GAO X, 1995, ONCOGENE, V11, P1395